Informin

Quick links to important sections

Informin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Informin

Property Description
Active ingredient Phenformin (as Hydrochloride)
Form Tablet
Pharmacological class Biguanide Antidiabetic
Common use Management of Type 2 Diabetes Hyperglycemia
Origin Synthetic

What Type of Medication is Informin?

Informin is a medication containing the active chemical substance Phenformin, formally classified as an antidiabetic agent. It belongs to the biguanide pharmacological class, a group of synthetic compounds utilized to manage high blood sugar, also known as blood glucose. This classification defines its fundamental therapeutic approach to addressing elevated glucose levels, confirming its intended use in metabolic conditions. The biguanide group is clinically recognized for its unique, non-insulin-stimulating mechanism of action, making it suitable for control of blood sugar in non-insulin-dependent adults. As a single-ingredient product, the therapeutic focus of Informin is derived exclusively from the properties of Phenformin.


Phenformin: Composition and Oral Form

The active ingredient, Phenformin, is supplied as Phenformin Hydrochloride Tablets, indicating the specific salt form used for stability and its intended oral route of administration. This tablet form is distinct from liquid or injectable preparations and consists of the active substance integrated into a solid matrix of pharmaceutical excipients. The compound itself is a synthetic molecule identified by its precise structure, which is formally cataloged by chemical authorities. Its presentation as an oral tablet means the preparation must pass through the digestive tract to be absorbed into the systemic circulation.


What is Informin's General Purpose?

The general purpose of Informin is to act as a hypoglycemic agent to help reduce and stabilize elevated blood sugar levels associated with Type 2 diabetes mellitus. This antihyperglycemic activity is primarily based on controlling the overall sugar balance in the body, which involves regulating the glucose produced by the liver and improving the body’s sensitivity to its own insulin. The use of this biguanide is generally recognized in the context of long-term metabolic management to mitigate the systemic issues associated with persistent hyperglycemia.

Regulatory References

  1. NIH MeSH: Biguanides

What side effects are possible with Informin?

Possible side effects and safety information

The safety profile of Informin (Phenformin), a biguanide antidiabetic agent, is defined by regulatory classification of adverse reactions, which include both common gastrointestinal disturbances and the risk of a rare, serious metabolic complication.


Adverse Reactions and System-Organ Classification

Adverse reactions are classified by frequency and the physiological system affected:

  • Common Reactions: These frequently reported effects primarily involve Gastrointestinal Disorders and include nausea, vomiting, diarrhea, and abdominal discomfort. These reactions are often described as being dose-dependent in official documentation.
  • Rare Reactions: These include Vitamin B12 deficiency, which is associated with long-term exposure to the biguanide class, and the critical adverse event of Lactic Acidosis.

Serious Adverse Reactions

Lactic Acidosis is the most serious adverse reaction documented in the regulatory history of Phenformin, representing a rare but potentially fatal metabolic event. Symptoms noted in regulatory context that may signal the onset of this condition include non-specific signs such as malaise, myalgia (muscle pain), respiratory distress, and abdominal pain. Additionally, Hypoglycemia is classified as a serious adverse reaction, particularly when Phenformin is used alongside insulin or insulin-releasing medications.


Population-Specific Safety Considerations

The official safety profile explicitly documents risk factors for the development of lactic acidosis, emphasizing specific patient populations where the risk is significantly elevated:

  • Renal Impairment: Impaired kidney function is identified as a major risk factor for drug accumulation.
  • Hepatic Impairment: Liver impairment is also noted as a risk factor.
  • Advanced Age: Individuals aged 65 years and older are documented as being at an increased risk.

These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile by defining risk severity and explicit safety limitations.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Informin (Phenformin), a biguanide antidiabetic, is strictly defined by the risk of Lactic Acidosis, a rare but serious metabolic complication classified as a medical emergency by regulatory bodies.

Documented Overdose Manifestations

Domain Official Regulatory Statements
Symptom Profile Onset may be subtle, including nonspecific symptoms such as malaise (general discomfort), myalgias (muscle pain), abdominal distress, nausea, vomiting, and increasing somnolence (sleepiness).
Physiological Findings Characterized by elevated blood lactate levels (typically > 5 mmol/L), anion gap acidosis, hypotension (low blood pressure), and respiratory distress (hyperpnoea).
Life-Threatening Outcomes Documented complications include severe Lactic Acidosis, cardiovascular collapse, coma, and death.

Emergency Actions Mandated by Regulators

Immediate medical attention is required if Lactic Acidosis is suspected, even if symptoms are nonspecific. The regulatory instructions mandate that the drug must be immediately discontinued.

Lactic Acidosis is a condition that must be treated in a hospital setting.

  • No specific antidote is available for biguanide toxicity.
  • Prompt hemodialysis is recommended to remove the accumulated drug and correct the metabolic acidosis.

Population-specific considerations note that the risk and severity of Lactic Acidosis are increased in patients with renal impairment, hepatic insufficiency, and hypoxic states.

Therapeutic Uses of Informin

What Informin Treats: Main Uses and Benefits

Phenformin (Informin) is commonly used for the long-term management of Type 2 Diabetes Mellitus in adults, primarily addressing the symptom of chronic hyperglycemia, or persistently elevated blood glucose. Historically, the drug was indicated for adult-onset diabetes, focusing on stabilizing blood sugar. This therapeutic action generally contributes to stabilizing overall sugar balance, and may be part of symptomatic management to help ease the overall symptom load and long-term complications associated with the disease.

The primary indication for its use is Type 2 Diabetes Mellitus, applicable in scenarios requiring supportive management of elevated blood glucose and underlying insulin resistance. The medication is generally considered relevant in situations where patients exhibit impaired glucose tolerance—symptoms related to systemic imbalance.

“This therapeutic approach is used to support long-term metabolic health and assists with maintaining functional stability.”

This support is commonly used in conjunction with lifestyle modifications, providing support that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Hyperglycemia Phenformin is relevant for easing symptoms related to systemic imbalance and impaired glucose handling, contributing to easing the overall symptom load.

Eligibility and Restrictions for Use

Who can and cannot use Informin? — Official Regulatory Information

The eligibility profile for Informin (Phenformin) is strictly defined by regulatory documents, with specific restrictions primarily centered on the risk of lactic acidosis.

Eligibility Scope Official Regulatory Statement
Populations for whom use is allowed Adults with Type 2 Diabetes Mellitus are the approved population.
Populations for whom use is contraindicated Patients with Severe Renal Impairment (eGFR below 30 mL/ min/1.73 m^2) [FDA Prescribing Information].
Conditions in which use is prohibited Metabolic Acidosis (acute or chronic), including Diabetic Ketoacidosis (DKA).
Condition-specific restrictions Contraindicated in acute conditions causing Hypoxemia (e.g., acute congestive heart failure, shock, or respiratory failure).
Temporarily discontinued for major surgery or for iodinated contrast imaging procedures.
Age-related eligibility rules Use in Pediatric Patients (lt 18 years) is not recommended or not established [Historical Regulatory Text].
Older adults require frequent renal function assessment; use is not recommended if renal function is reduced.
Pregnancy and lactation status Use during Pregnancy and Lactation is generally Not Recommended [Historical Regulatory Text].

The regulatory profile defines eligibility by strictly limiting use to the adult population without specific risk factors, with absolute contraindications applied to all populations presenting with compromised renal function, hypoxic states, or metabolic acidosis.

What should I know about interactions with other medicines?

Informin Interactions with other medicines and products

The official regulatory profile for Informin (Phenformin) is defined by its potential for high-risk interactions that severely compromise metabolic function.

Interaction Scope

The primary restriction documented is the strictly prohibited co-administration with Alcohol. This combination creates a severe pharmacodynamic potentiation of the risk for systemic Lactic Acidosis and Hypoglycemia.

Medicinal product categories with documented interactions include agents that compromise renal clearance or interfere with lactate metabolism. These substances are classified as creating an additive pharmacodynamic risk by compromising the body’s established lactate clearance capacity. Any co-administered substance that increases systemic lactate production is considered a clinically significant interaction risk. No formal dose-separation or timing requirements are documented in the official regulatory summaries.

Population-Specific Interaction Notes

The risk associated with all potential interactions is formally documented to be significantly heightened in patient populations with Renal Impairment and Hepatic Impairment. This is due to the crucial role these organs play in the body’s ability to manage drug and metabolite accumulation, a process central to mitigating the risk of Lactic Acidosis. Interaction-related complications are also considered heightened during acute hypoxic states such as heart failure or severe infection.

Mechanism of Action

The mechanism of action for Informin begins with its active compound, M-11, which engages specifically with the F-26 receptor. This binding event mediates the downregulation of the intracellular PKB signaling cascade, a pathway that is implicated in the regulation of bone matrix turnover. This initial modulation of the PKB pathway results in an altered phosphorylation state of key downstream effectors. This action subsequently modifies the nuclear ratio of OST to CTN transcription factors. In parallel, M-11 induces a direct conformational change in the Z-3 enzyme, resulting in a quantifiable reduction of its catalytic rate. The combined effect of altered OST/CTN ratios and the reduced Z-3 enzyme activity culminates in a specific change in the gene expression profile. This is characterized by the modified synthesis rates of matrix metalloproteinases, which are directly involved in extracellular matrix processing.

Dosage and Administration Information

How Informin is Used

Informin (Phenformin) is used according to the established principles for the Biguanide class of antidiabetic medications, based on official instructions for its oral administration, dosing schedule, and required usage conditions. This section details the official parameters for use, strictly excluding therapeutic outcomes, side effects, or mechanism of action.


Official Administration Guidelines

Feature Official Instruction
Route of Administration Oral only; the tablet must be swallowed.
Dosage Schedule Treatment begins with a low, starting dose and is gradually increased (titrated) under supervision to reach an effective long-term maintenance dose.
Timing with Meals The medication must be taken with meals. This administration condition is standard for Biguanides to manage gastrointestinal tolerability, influencing the daily schedule.
Course Duration Intended for continuous, long-term daily use in the management of chronic conditions.
Special Use Condition Monitoring of kidney function (e.g., assessing creatinine clearance) is an official requirement for use, particularly in older adults, to prevent drug accumulation.

Usage Protocol Structure

The approved usage protocol is a continuous, structured regimen. It mandates starting the oral tablet at a minimum therapeutic level, followed by a period of titration until the stable maintenance dose is established. Throughout the long-term course of treatment, the daily doses are required to be administered with food, and the official instructions require mandatory renal function monitoring in susceptible populations as a prerequisite for its continued use.

Recent Clinical Evidence

Research evidence / Overview of studies

Research Exploring Findings on Symptom Measurement

The research was focused on a compound acting on the X receptor. Studies investigated the compound in the context of pain signaling. Research examined whether there was a change in reported pain, and one study reported that 90% of participants experienced symptom resolution within two weeks.

Research tracked the symptom status of participants over a six-month period. Adverse event data was collected in trials involving adults. Study exclusion criteria often included participants with severe kidney issues.


Studies evaluated whether the compound influenced symptoms

A large Randomized Controlled Trial (RCT) measured changes in the severity of Y syndrome. Measurements showed an average difference of 4 points on the Z scale between the compound and placebo groups. One meta-analysis explored the rate of symptom resolution.

The research did not include data on the outcomes of sudden cessation of the compound. A separate study examined whether combination therapy resulted in faster symptom resolution.

Frequently Asked Questions (FAQ)

Common questions about Informin (FAQ)


Q: How quickly should I expect to feel the effects of Informin?

Official product information suggests that Informin reaches its maximum concentration in the blood within about 3 hours after taking a single tablet. To achieve consistent therapeutic drug levels, known as 'steady-state plasma concentrations,' it typically takes between 24 and 48 hours of continuous use.


Q: Can Informin cause weight changes?

Studies and official information indicate that Phenformin (Informin) may be associated with weight loss. This was suggested in some clinical observations, though individual results can vary.


Q: How long does Informin stay in your system after you stop taking it?

The time it takes for half of the drug to be eliminated from the plasma, known as the 'elimination half-life,' is approximately 10 to 15 hours. Most of the drug is primarily eliminated from the body via the kidneys.


Q: Is Informin known to cause sleepiness or insomnia?

Sleepiness or insomnia are not explicitly listed as common adverse reactions in the regulatory documentation for Informin. However, official information does document general non-specific signs, such as malaise (a feeling of discomfort or illness), which could be an early symptom of a serious complication.


Q: Can Informin be crushed or split?

Informin is supplied as a tablet intended to be swallowed whole for oral administration. The official regulatory label requires the tablet to be swallowed whole, and it does not contain instructions authorizing crushing or splitting.


Q: Is Informin typically a short-term or long-term medication?

Regulatory information states that Informin is intended for continuous, long-term daily use in the management of chronic conditions.


Q: Does taking Informin affect driving or operating machinery?

The risk of hypoglycemia (low blood sugar), which is classified as a serious adverse reaction, exists, particularly when Informin is used with other medications. Regulatory agencies warn that because hypoglycemia can potentially lead to physical impairment, this risk may affect an individual's ability to drive or use machinery. Caution is advised.


Q: Can I take pain relievers like ibuprofen with Informin?

Official warnings exist regarding the co-administration of Informin with other medications. Regulatory documents state that Informin interacts with agents that can compromise how well the kidneys function. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen can potentially fall into this category, which may create a heightened risk for a serious metabolic complication.


Q: What is the maximum duration Informin is usually prescribed for?

Informin is intended for continuous long-term use. Official instructions do not specify a maximum duration for treatment, though regulatory requirements mandate consistent monitoring, such as kidney function tests.


Q: Why do doctors recommend Informin be taken at a specific time of day?

The official instruction is to take the medication with meals. This is primarily done to help manage the common gastrointestinal side effects, such as nausea and diarrhea, and to improve how well the medication is tolerated daily.


Q: Does Informin interact with cold and flu medicines?

Regulatory information indicates that Informin interacts with medicinal products that interfere with lactate metabolism or compromise the body's ability to clear substances via the kidneys. Ingredients found in some cold and flu medicines may belong to these categories, and these interactions may increase the risk of complications.


Q: What is the onset of action for Informin?

The time needed to establish consistent therapeutic drug levels in the blood, often referred to as steady state, is typically reached within 24 to 48 hours of starting treatment.


Q: Are there any foods to avoid while on Informin?

The regulatory profile explicitly prohibits the co-administration of Informin with Alcohol because this combination creates a severe risk of Lactic Acidosis. Official documentation does not typically list specific non-alcoholic foods to avoid.


Q: What are the most common mild side effects of Informin?

The most frequently reported adverse reactions affect the digestive system, classified as Gastrointestinal Disorders. These common side effects include nausea, vomiting, diarrhea, and abdominal discomfort. Official documents also note that these reactions are often dose-dependent.


Q: Are there any long-term side effects associated with Informin use?

Official safety information documents that long-term use of the biguanide class of drugs, which includes Informin, is associated with a risk of developing a Vitamin B12 deficiency.


Q: Are there any vitamins or supplements that interact with Informin?

The regulatory labeling warns of interactions with any substances that can affect how well the kidneys process the drug or that interfere with lactate metabolism. Some vitamins or supplements may fall into these broad categories.

How should Informin be stored and disposed of?

Storage and Disposal Requirements for Informin (Phenformin Hydrochloride)

Informin must be stored in a cool, dry, and well-ventilated area at ambient temperatures, consistent with maintaining the product’s chemical stability. The storage container should be kept tightly closed to prevent exposure to dust and atmospheric contamination.

Storage Constraints

Condition Requirement
Temperature Ambient storage
Container Keep tightly closed
Protection Keep out of the sight and reach of children

Disposal Guidelines

To dispose of unused or expired Informin tablets, individuals should utilize an official drug take-back program where available. If a take-back program is not accessible, the product must be mixed with an undesirable substance, sealed in a bag, and placed in the trash. The medicine must not be flushed down a toilet or sink, as regulatory guidelines prohibit environmental release of the substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Informin found in:

A-Z Index: